APA (7th ed.) Citation

Ebert, N., Rosar, F., Burgard, C., Bartholomä, M., Maus, S., Hein, C., . . . Khreish, F. (2026). Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: Preliminary evidence from a pilot experience. EJNMMI Research, 16(1), 1. https://doi.org/10.1186/s13550-026-01408-w

Chicago Style (17th ed.) Citation

Ebert, Niklas, Florian Rosar, Caroline Burgard, Mark Bartholomä, Stephan Maus, Connor Hein, Arne Blickle, Samer Ezziddin, and Fadi Khreish. "Outcome and Safety of Single-dose Docetaxel–augmented Targeted Radionuclide Therapy Using [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in Treatment-refractory MCRPC: Preliminary Evidence from a Pilot Experience." EJNMMI Research 16, no. 1 (2026): 1. https://doi.org/10.1186/s13550-026-01408-w.

MLA (9th ed.) Citation

Ebert, Niklas, et al. "Outcome and Safety of Single-dose Docetaxel–augmented Targeted Radionuclide Therapy Using [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in Treatment-refractory MCRPC: Preliminary Evidence from a Pilot Experience." EJNMMI Research, vol. 16, no. 1, 2026, p. 1, https://doi.org/10.1186/s13550-026-01408-w.